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Introduction
Mental health is one of the most significant, and often overlooked, aspects of the
healthcare system. The consequences of a neglected psyche can trigger substantial damage to
the physical body over time. Unlike preceding generations, today’s society has become
inundated with constant technological advancements and an unhealthy obsession with
productivity. This situation can contribute to a lack of meaningful social connections,
impossible to reach societal standards, a lack of a work-life balance, and perhaps most
importantly, an overwhelming emotional burden.1 Unfortunately, this emotional burden is often
perceived as an impediment in a productivity driven world, rather than as a precursor to harmful
mental and physical health outcomes. It is no wonder, then, that clinical research in medicine
continues to uncover connections between a lack of emotional wellbeing and the risks of
developing chronic diseases. Evidence now exists demonstrating the means by which persistent
stress and anxiety can essentially cause damage to the brain by altering neural pathways. Over
time, this brain damage can lead to neuropsychiatric disorders such as chronic depression,
bipolar disorder, PTSD, and dementia.
Major depressive disorder (MDD), also known as unipolar depression, is a serious
chronic mood disorder that has a lifetime prevalence of 16.6% in the US. According to the
World Health Organization it is the leading cause of disability.2 It can cause severe symptoms
that affect one’s emotions, thoughts, social life, physical health, sleep habits, eating habits,
ability to partake in routine daily activities of living, and even the will to live. Although
numerous well-established treatments for MDD are available (e.g., anti-depressants,
psychotherapy, somatic interventions, electroconvulsive therapy (ECT), transcranial magnetic
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stimulation (TMS), et cetera), a large population of patients do not respond to these conventional
treatments. One of the largest and most comprehensive clinical studies on MDD, Sequenced
Treatment Alternative to Relieve Depression, demonstrated that improvement of depressive
symptoms is only achieved in about 30% of patients after the first antidepressant medication
trial. 3 Moreover, the odds of
improvement lessen with
subsequent antidepressant
medication trials. Clinically,
patients who fail at least two
trials of antidepressant drugs
from different pharmacologic
classes are categorized as
having treatment-resistant
depression (TRD). The
foregoing findings have vast implications for the wellbeing of patients experiencing treatment
failures.
Chronic suicidal ideation (SI), a common symptom of TRD, puts these patients are at
greater risk of engaging in suicidal behaviors.4 Suicide is a psychiatric emergency, for which
there are no currently approved rapid onset medical treatments. The standard available
pharmacological antidepressants can take weeks to months to achieve desired effects. As a
result, the estimated 400,000 individuals per year who seek emergency treatment for suicidal
thoughts and behavior often do not get timely relief. 5 According to the CDC, suicide is the 10th
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leading cause of death in the US and it takes the lives of approximately 45,000 Americans every
year. 5
For decades clinicians and scientists have been searching for an alternative to rapidly
treat patients with TRD. This dilemma may be partly resolved for some patients. A new use for
an old drug, ketamine, promises to be effective for treatment of TRD. This new role for
ketamine will be explored with particular emphasis on whether it is effective, and if so, how
durable its benefits are.

Historical Context
Prior to the discovery of ketamine, phencyclidine (PCP) was one of the main anesthetics
used. It not only caused the adverse effect of delirium, but also became a drug of abuse. These
disadvantages prompted the search for a better agent. In 1962 chemists discovered ketamine, a
structural analog of phencyclidine with one-tenth the potency of PCP. 6 Within two years the
first human trials with ketamine began to explore its potential applications. 6 In 1970 the FDA
approved ketamine for use in anesthesia. Historically, ketamine has been a popular anesthetic
because it produces analgesia/sedation, amnesia, and lacks significant respiratory depression.
Given ketamine’s ability to preserve cardiorespiratory stability within a large therapeutic
window, anesthesiologists and critical care specialists regard it as an invaluable resource for
anesthesia and sedation. However, during the late 1970s, after gaining popularity in the medical
field, ketamine became more readily available and subsequently became a source of problems.
Due to its effects of disassociation, ketamine was used and sold recreationally leading to
problems with drug abuse and addiction. 6 As a result, ketamine eventually fell out of favor as a
first line anesthetic/sedative agent and is now considered a schedule III-controlled substance.
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For decades afterwards many medical providers have feared exploring the possibilities
of ketamine’s use outside of anesthesia. Despite its negative reputation, some clinicians still
maintained a healthy curiosity in its potential. Beginning in the mid-1990s at Yale University,
researchers started exploring ketamine’s use in depression. 6 Over the last two decades and
counting, data from a growing number of clinical trials have been compiled into dozens of
review papers, meta-analysis, and retrospective studies. The evidence from these data suggest
that in small doses, ketamine can produce a rapid, effective treatment for patients with TRD.
Interestingly, in March of 2019, the FDA approved intra-nasal esketamine (Spravato™) (a
doubly potent chemical cousin to ketamine) to be used in conjunction with an oral antidepressant
for treatment resistant MDD.7 It is not known whether its side effect profile, dosage, route of
administration and antidepressant actions are superior, equal to, or inferior to those of ketamine.
Thus, more research was necessary to characterize treatment of depression with ketamine and
esketamine. Recent investigations are helping to better understand their roles.

Background/Science
The field of psychiatry is enthusiastic about the findings that ketamine has rapid-onset
antidepressant effects in patients with TRD. However, the exact mechanism of this therapeutic
effect remains a topic of debate. Ketamine’s primary known mechanism of action involves
blocking the N-methyl-D-aspartate receptor (NMDAR), a glutamate receptor found in nerve cells
of the brain.8 Glutamate is the predominant neurotransmitter in the brain and is involved in
every major excitatory brain function. Its role is to facilitate communication cross networks of
cells in order to execute complex central nervous system (CNS) functions such as hearing,
vision, and movement. 8 Ketamine blocks this sensory input which accounts for most of its
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known effects in anesthesia. However, it is unknown if this blockade of NMDAR is the primary
contributor to ketamine’s antidepressant effects.

Figure 1. Potential MOA of Ketamine in Treating Treatment-Resistant Depression (intext
cite) Abbreviations: BDNF, brain derived neurotrophic factor; GABA, λ-aminobutyric acid; NMDA, N-methyl-Daspartate.

A second contributing mechanism of action (MOA) that might explain ketamine’s
antidepressant effects was theorized in 2017 by Ionescu and Papakostas.9 Ketamine increases
expression of brain-derived neurotrophic factor (BDNF), a protein that promotes the survival of
neurons in the CNS. 9 This elevation in BDNF in the hippocampus is thought to promote neuron
and synaptic repair which likely contributes to ketamine’s rapid antidepressant-like effects.6 In
other words ketamine permits neuroplasticity, which is crucial given depression’s known
association with prolonged neurodegeneration. 9
A final important mechanism of action of ketamine is its reduction of inflammatory
cytokines10, which have been linked to mood disorders. Interestingly, ketamine is the only
anesthetic drug to have a strict inhibitory effect on pro-inflammatory cytokine signals. 10
Clearly, ketamine has multiple mechanisms of action which work simultaneously, making it a
unique drug in comparison to traditional antidepressant medications. Traditional medications
mostly attempt to increase the level of neurotransmitters such as norepinephrine, dopamine and
serotonin. The delay in effectiveness of these antidepressants has suggested that medication-
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induced changes in neurotransmitters are still several steps away targeting the root cause of
depression. In contrast to other non-pharmacological forms of depression therapy, ketamine is
widely available and its use does not require providers trained and equipped to use specialized
devices such as with ECT and TMS. 11 Needless to say, it is an exciting time for the field of
psychiatry to explore the possibilities of ketamine’s rapid improvement of symptoms in TRD.

Discussion of Findings
By the late 1990s there was a growing body of preclinical research implicated that
ketamine’s NMDA receptor antagonist behavior may have antidepressant activity. The
psychiatric community was eager to start trialing. In 2000, the first clinical trial reporting the
antidepressant effects of ketamine was conducted by R.M Berman et al. and published by
Biological Psychiatry Journal.12 This randomized, double-blinded study tested seven subjects
with major depression over a period of 2 days. Participants received either a saline solution
(placebo) or ketamine (control) administered intravenously at 0.5 mg/kg over a period of 40
minutes in this study. They were evaluated at baseline and post infusion at 80 minutes, 230
minutes, 24 hours, 48 hours and 72 hours after starting infusion. The Hamilton Depression
Rating Scale (HDRS) was used to evaluate mood changes pre and post infusion. The results of
this study showed low dose IV infusions of ketamine significantly reduce HDRS scores
compared to saline (placebo). Patients reported a diminution of depressive symptoms within 3
days post infusion. Ketamine’s rapid onset of action in contrast to that of traditional
antidepressants generated considerable excitement.
In 2006, with the support of the National Institute of Mental Health, Zarate et al. designed
another randomized, placebo-controlled, double-blind crossover study to determine the effects of
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IV infusions of ketamine vs placebo on TRD over the period of a year.13 This study was higher
in budget, had eighteen subjects and lasted much longer than the previous study. Results showed
that subjects receiving ketamine showed 71% of the subjects had a significant improvement in
depression within 110 minutes after injection. The remission response remained significant for
up to a week in 35% of the subjects. This study was important for the trajectory of ketamine as a
viable option for TRD because it points to a potential for longer lasting effects. Still, some
skeptics regarded the antidepressant effects of ketamine to be a result of its psychoactive nature
(mind-altering effects) rather than a true pathological improvement of neurological pathways
leading to depression.
In a 2013 study by Murrough et al., for the first time, ketamine was compared with a
psychoactive placebo, midazolam.14 This was a two-site, parallel arm, randomized controlled
trail of a single infusion of ketamine compared to an infusion of midazolam. Using the
Montgomery-Asberg Depression Rating Scale (MADRS), the researchers assessed outcomes and
found that the ketamine group had a greater improvement in the MADRS score than the
midazolam group 24 hours after treatment. A response rate of 64% improvement for symptoms
of depression was found for the patients
who received ketamine as compared
with 28% in those who received the
midazolam. This study mitigated some
of the hypotheses that its role was tied in
its mind-altering effects, rather than its
unique MOA as an NMDA receptor

7

modulator, furthering its promise as a novel treatment option for TRD.
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled
trials of ketamine in the rapid treatment of major depressive episodes, reported by Mcgirr et al.
concludes that single administrations of ketamine are efficacious in the rapid treatment of
unipolar and bipolar depression. Additional research is recommended to determine optimal
dosing schedules, route, treatment schedules, and the potential efficacy of other glutamatergic
agents.15

Drawbacks and Concerns
Over the decades numerous studies, such as the above, have been published supporting
the conclusion that ketamine does in fact seem to improve TRD in as little as two hours with
effects lasting for several days up to a few weeks. Other studies successfully trialed repeat IV
infusions of ketamine followed by as needed maintenance doses for providing longer term relief
of TRD.16 Even so, valid concerns remain regarding the potential for abuse, psychotomimetic
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side effects, and its long-term safety profile. Nonetheless, one may argue that reliance upon low,
subanesthetic doses in ketamine therapy for depression would safeguard against these concerns.17
Currently, trials and research persevere in studying these effects and in establishing the best
route and dose of administration of ketamine to safely and effectively treat TRD. In a systematic
review and meta-analysis of ketamine and other NMDA receptor antagonists in the treatment of
MDD by Newport et al., it was concluded that the fleeting nature of ketamine’s therapeutic
benefit, coupled with it’s potential for abuse and neurotoxicity, suggest that its use in the clinical
setting warrants caution. 17 Still, off-label use of ketamine for patients with TRD continues to
rise in the US, where it's estimated approximately 60-100 ketamine clinics currently operate. 18

Conclusion
The predominant findings suggest that ketamine does, in fact, prove to be effective in
rapid improvement of symptoms in patients with TRD. As more research continues to emerge,
new questions arise. These questions vary from the potentials for abuse, long term side effect
profile, best route and dosage of administration, the exact mechanism of action, et cetera.
Although ketamine has been proven to have rapid and robust antidepressant effects, often
apparent within hours post infusion, its effects seem to rarely persist longer than 2 weeks. 15
Studies demonstrating that ketamine’s antidepressant effects can be sustained with serial
infusions are lacking. 15 This deficiency would be an excellent area of future investigation.
Further research may be necessary to elucidating the exact mechanism of action that works on
reversing symptoms of TRD. While the research community resumes its search for answers to
these questions, patient’s with TRD continue to suffer. It is estimated about 5 to 6 million
people have depression which is resistant to conventional pharmacologic, psychologic or somatic
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treatments.19 Clearly ketamine has a role in clinical practice where it is already being used offlabel in up to 100 ketamine clinics in the United States today. However, these clinics are often
private ones where wealthy patients who can afford this off-label treatment are willing to pay
high costs for these infusions, which health insurance does not cover. 18 Unfortunately, these
costs are out of reach for most patients.
As pharmaceutical companies continue their search for the most effective approach to
utilizing the antidepressant effects of ketamine, people continue to suffer from inadequately
treated depression and chronic suicidality. 20 It is important to evaluate what we know of
ketamine’s effects and its potential in patients with TRD who experience suicidal thoughts or
attempts. In 2017, a meta-analysis written by Wilkinson et al.21 showed ketamine has a role in
reducing suicidality, independent of its effect of improving depression. Many of those who are
diagnosed with TRD also suffer with chronic suicidality. As a result, these people are often seen
in an emergency room setting and either sent to a psychiatric facility or advised to follow up with
their primary care doctors to be prescribed medications that don’t take effect for weeks,
sometimes months. The field of emergency medicine has much to gain by the use of this fastacting antidepressant. In an article published by the Emergency Medicine Resident Association
(EMRA), residents report their experience, “The unsettling reality is that the dearth of acute
interventions means we discharge many of our depressed patients home without first being able
to significantly reduce their symptoms. This is particularly worrisome in light of data suggesting
that the risk of suicide increases immediately after discharge. But it doesn’t have to be this
way”.22 Although we are still years away from an outpatient approval of ketamine, it may be
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time to consider the role of ketamine in emergency medicine for patients at immediate risk of
suicidality.
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